Search

Displaying results 4951 - 4960 of 7602 in total
  1. Drug

    Pecilocin

    go.drugbank.com/drugs/DB13459
    Experimental

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  2. Drug

    Saracatinib

    go.drugbank.com/drugs/DB11805
    Investigational

    Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.

  3. Drug

    Ligandrol

    go.drugbank.com/drugs/DB13934
    Investigational

    Ligandrol is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis.

  4. Drug

    TC-6987

    go.drugbank.com/drugs/DB14854
    Investigational

    TC-6987 is under investigation in clinical trial NCT01296087 (TC-6987 for the Treatment of Mild to Moderate Asthma).

  5. Drug

    LTX-109

    go.drugbank.com/drugs/DB12711
    Investigational

    LTX-109 has been investigated for the treatment of Atopic Dermatitis, Mild Eczema/Dermatoses, and Gram-positive, Skin Infections.

  6. Drug

    Tantalum

    go.drugbank.com/drugs/DB12859
    Investigational

    Tantalum has been investigated for the treatment and prevention of Osteoarthritis, Knee Osteoarthritis, Intraoperative Bleeding, and Adolescent Idiopathic Scoliosis.

  7. Drug

    JNJ-17216498

    go.drugbank.com/drugs/DB17087
    Investigational

    JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.[A253997]

  8. Drug

    Adelmidrol

    go.drugbank.com/drugs/DB16083
    Investigational

    Placebo for Gynecologic Oncology Patients Affected by Vaginitis).

  9. Drug

    Coprelotamab

    go.drugbank.com/drugs/DB16380
    Investigational

    Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 Humanized Monoclonal Antibody for Injection).

  10. Drug

    Toralizumab

    go.drugbank.com/drugs/DB16384
    Investigational

    Toralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).